Literature DB >> 12187958

Immunohistochemical markers for prognosis of oligodendroglial neoplasms.

Andrey Korshunov1, Andrey Golanov, Regina Sycheva.   

Abstract

Despite numerous previous studies, oligodendrogliomas continue to generate considerable controversy in the identification of prognostic factors, including single histopathological patterns, and grade of tumor malignancy. The prognostic significance of various pathological and immunohistochemical factors has been intensively examined but numerous studies have yielded conflicting results. In the present study, biopsy samples of 123 oligodendrogliomas were examined immunohistochemically to evaluate a possible association between expression of various tumor-associated antigens and clinical outcome. Both the progression-free and overall survival times were significantly reduced for high-grade tumors, for Ki-S1 labeling index (LI) > 10%, for p27 LI < 20% and for p18, p53, and vascular endothelial growth factor (VEGF)-positive tumors. For low-grade tumors survival rates were significantly reduced for p27 LI less than 20%, whereas high-grade oligodendrogliomas with Ki-S1 LI greater than 10%, and with p18 positivity revealed significantly shortened survival times. We found no differences in survival times in patients with or without p 14ARF, p21, mdm2, and pRb immunoreactivity. Multivariate analysis revealed that risk of oligodendroglioma progression is associated with high-grade tumors, with Ki-S1 LI > 10%, and with p27 LI < 20%; whereas risk of death is associated with high-grade tumors, with Ki-S1 LI > 10%, and with p18 positivity. CART modeling process identified four final groups of oligodendroglioma patients: (1) thirty-nine patients with low-grade tumors and p27 LI > 20%; (2) twenty patients with low-grade tumors and p27 LI < 20%; (3) thirty-four patients with high-grade tumors and Ki-S1 LI < 10%; and (4) thirty patients with high-grade tumors and Ki-S1 LI >10%. In summary, both the p27 and Ki-S1 scores were found to be the strong predictors of oligodendroglioma outcome together with the WHO tumor grade and they seem to be useful for assessing individual prognosis in routinely processed specimens.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12187958     DOI: 10.1023/a:1016270101321

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  106 in total

Review 1.  Integration of the pRB and p53 cell cycle control pathways.

Authors:  C L Stewart; A M Soria; P A Hamel
Journal:  J Neurooncol       Date:  2001-02       Impact factor: 4.130

2.  Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.

Authors:  J S Smith; A Perry; T J Borell; H K Lee; J O'Fallon; S M Hosek; D Kimmel; A Yates; P C Burger; B W Scheithauer; R B Jenkins
Journal:  J Clin Oncol       Date:  2000-02       Impact factor: 44.544

3.  Oligodendrogliomas in the CT/MR-era.

Authors:  M A Leonardi; C B Lumenta
Journal:  Acta Neurochir (Wien)       Date:  2001-12       Impact factor: 2.216

4.  Proliferating cell nuclear antigen and Ki-67 immunohistochemistry of oligodendrogliomas with special reference to prognosis.

Authors:  S Heegaard; H M Sommer; H Broholm; O Broendstrup
Journal:  Cancer       Date:  1995-11-15       Impact factor: 6.860

5.  Promoter hypermethylation and homozygous deletion of the p14ARF and p16INK4a genes in oligodendrogliomas.

Authors:  T Watanabe; M Nakamura; Y Yonekawa; P Kleihues; H Ohgaki
Journal:  Acta Neuropathol       Date:  2001-03       Impact factor: 17.088

6.  Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization.

Authors:  S H Bigner; M R Matthews; B K Rasheed; R N Wiltshire; H S Friedman; A H Friedman; T T Stenzel; D M Dawes; R E McLendon; D D Bigner
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

7.  Molecular genetic analysis of non-astrocytic gliomas.

Authors:  C Y Tong; H K Ng; J C Pang; A B Hui; H C Ko; J C Lee
Journal:  Histopathology       Date:  1999-04       Impact factor: 5.087

8.  Proliferation and cell death in oligodendrogliomas.

Authors:  S B Wharton; F A Hamilton; W K Chan; K K Chan; J R Anderson
Journal:  Neuropathol Appl Neurobiol       Date:  1998-02       Impact factor: 8.090

9.  Homozygous deletions of the CDKN2C/p18INK4C gene on the short arm of chromosome 1 in anaplastic oligodendrogliomas.

Authors:  U Pohl; J G Cairncross; D N Louis
Journal:  Brain Pathol       Date:  1999-10       Impact factor: 6.508

10.  p27/kip1 expression in human astrocytic gliomas.

Authors:  R Piva; P Cavalla; S Bortolotto; S Cordera; P Richiardi; D Schiffer
Journal:  Neurosci Lett       Date:  1997-10-03       Impact factor: 3.046

View more
  5 in total

1.  Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.

Authors:  Sridharan Gururangan; Susan N Chi; Tina Young Poussaint; Arzu Onar-Thomas; Richard J Gilbertson; Sridhar Vajapeyam; Henry S Friedman; Roger J Packer; Brian N Rood; James M Boyett; Larry E Kun
Journal:  J Clin Oncol       Date:  2010-05-17       Impact factor: 44.544

2.  Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma.

Authors:  Keith L Ligon; Emmanuelle Huillard; Shwetal Mehta; Santosh Kesari; Hongye Liu; John A Alberta; Robert M Bachoo; Michael Kane; David N Louis; Ronald A Depinho; David J Anderson; Charles D Stiles; David H Rowitch
Journal:  Neuron       Date:  2007-02-15       Impact factor: 17.173

3.  Molecular genetics of adult grade II gliomas: towards a comprehensive tumor classification system.

Authors:  Dominique Figarella-Branger; Corinne Bouvier; André Maues de Paula; Karima Mokhtari; Carole Colin; Anderson Loundou; Olivier Chinot; Philippe Metellus
Journal:  J Neurooncol       Date:  2012-08-14       Impact factor: 4.506

4.  Defective DNA double-strand break repair underlies enhanced tumorigenesis and chromosomal instability in p27-deficient mice with growth factor-induced oligodendrogliomas.

Authors:  W L See; J P Miller; M Squatrito; E Holland; M D Resh; A Koff
Journal:  Oncogene       Date:  2010-01-11       Impact factor: 9.867

5.  Genotyping low-grade gliomas among Hispanics.

Authors:  Andrés Felipe Cardona; Leonardo Rojas; Beatriz Wills; José Behaine; Enrique Jiménez; Fernando Hakim; Nicolás Useche; Sonia Bermúdez; Oscar Arrieta; Juan Armando Mejía; Juan Fernando Ramón; Hernán Carranza; Carlos Vargas; Jorge Otero; Diego González; July Rodríguez; León Darío Ortiz; Hernando Cifuentes; Carmen Balaña
Journal:  Neurooncol Pract       Date:  2016-01-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.